ReviewCureus2024
Diabetic Macular Edema Management: A Review of Anti-Vascular Endothelial Growth Factor (VEGF) Therapies.
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Correlation between the optical density ratio of subretinal fluid in OCT images and visual outcome in eyes with diabetic MacularEdema.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Safety and Efficacy of Brolucizumab in the Treatment of Patients with Diabetic Macular Edema and Diabetic Retinopathy: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
- Safety and efficacy of topical OCS-01 ophthalmic suspension for the treatment of diabetic macular oedema: stage 1 of a multicentre, double-blind, randomised, vehicle-controlled phase 2/3 trial.EClinicalMedicine · 2026Article
- Prognostic Imaging Biomarkers in Diabetic Macular Edema Treated with Anti-VEGF: A Multicenter AI Perspective.Ophthalmology and therapy · 2026Article
- Retinal Outcomes in Diabetes: Antihyperglycemic Therapy, EWDR, and Perioperative Considerations.Biomedicines · 2026Review
- Development of a predictive model based on aqueous cytokines data for response to anti-VEGF therapy in diabetic macular edema.Eye and vision (London, England) · 2026Article
- Article
- Therapeutic Outcomes of Anti-VEGF Agents Versus Corticosteroids in Diabetic Macular Edema: A Comparative Review.International journal of molecular sciences · 2026Review
- Systemic factors associated with poor anatomical response to anti-VEGF therapy in patients with diabetic macular edema: evidence from a large clinical cohort.Frontiers in endocrinology · 2026Article
- The role of interleukin-6 in diabetic retinal disease: pathophysiology and therapeutic targeting.Frontiers in immunology · 2026Review
- Pharmacological Treatment for Diabetic Macular Edema: A 2025 Update on Durability and Multi-Target Therapies.Drug design, development and therapy · 2026Review
- Comparative value of retinal structural features versus systemic inflammatory and renal indicators in predicting short-term anti-VEGF response in diabetic macular edema: focus on OCT biomarkers.Frontiers in medicine · 2026Article
- Clinical and optical coherence tomography predictors of spontaneous resolution of diabetic macular edema: incremental value of the subfoveal large choroidal vessel layer thickness ratio.Frontiers in medicine · 2026Article
- Research advances in the translational application of anti-VEGF combined with subthreshold micropulse laser therapy for refractory diabetic macular edema.American journal of translational research · 2026Review
- Oxytocin Mitigates VEGF Expression in Differentiated RPE cells - A Novel Therapeutic Approach for Diabetic Retinopathy.Biomedical & translational science · 2026Article
- Beyond Vision: Prospective Real-World Evaluation of Quality-of-Life and Caregiver Burden in Diabetic Macular Edema Treated with Fluocinolone Acetonide (IluvienOphthalmology and therapy · 2026Article
- Patient and Physician Perspectives on the Management of Diabetic Macular Edema.Ophthalmology and therapy · 2026Article
- Efficacy of aflibercept in vitrectomized vs. non-vitrectomized eyes with diabetic macular edema: a prospective study.International journal of retina and vitreous · 2025Article
- Diabetic retinopathy in rural communities: a review of barriers to access of care and potential solutions.Annals of medicine · 2025Review
- Are statins a promising therapeutic strategy for macular edema? Insights from a systematic review and meta-analysis.International journal of retina and vitreous · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic macular edema (DME) is a major cause of vision impairment in diabetic individuals, characterized by fluid accumulation in the macula due to a breakdown of the blood-retinal barrier (BRB). This review article explores the role of anti-vascular endothelial growth factor (anti-VEGF) therapies in the management of DME. Anti-VEGF treatments, including ranibizumab, bevacizumab, and aflibercept, have revolutionized DME management by targeting VEGF, a key mediator in DME pathogenesis. We critically examined the efficacy of these therapies in reducing macular edema and improving visual acuity, assessed their safety and tolerability, and explored the variability in treatment response. The review highlights the latest advancements and future directions in anti-VEGF therapy, including novel drug delivery systems and emerging treatment paradigms. By providing a comprehensive overview of current anti-VEGF therapies, this review seeks to inform clinical practice, guide future research, and contribute to improved patient outcomes in DME management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.